

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014037 A3

(51) International Patent Classification⁷: A61K 39/02,
39/385, 39/39

(21) International Application Number:
PCT/US2004/025477

(22) International Filing Date: 6 August 2004 (06.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/493,389 6 August 2003 (06.08.2003) US

(71) Applicant (for all designated States except US): THE
GOVERNMENT OF THE UNITED STATES OF
AMERICA, as represented by THE SECRETARY,
DEPARTMENT OF HEALTH AND HUMAN SER-
VICES [US/US]; National Institutes of Health, Office of
Technology Transfer, 6011 Executive Blvd, Suite 325,
Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEE, Che-Hung,

Robert [US/US]; 116 Amberleigh Drive, Silver Spring,
MD 20905 (US). FRASCH, Carl, E. [US/US]; 13100
Burlwood Drive, Rockville, MD 20853 (US).

(74) Agent: SIMPSON, Andrew, H.; Knobbe, Martens, Olson
and Bear, LLP, 2040 Main Street, Fourteenth Floor, Irvine,
CA 92614 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES

Comparison between conjugation Method A and
conventional reductive animation conjugation by HPSEC at
280 nm using a Waters Ultrahydrogel 2000 column



(57) Abstract: Abstract of the
Disclosure Methods for synthesis and
manufacture of polysaccharide-protein
conjugate vaccines at high yield
are provided. The methods involve
reaction of a hydrazide group on one
reactant with an aldehyde or cyanate
ester group on the other reactant. The
reaction proceeds rapidly with a high
conjugation efficiency, such that a
simplified purification process can
be employed to separate the conjugate
product from the unconjugated protein
and polysaccharide and other small
molecule by-products.

WO 2005/014037 A3



FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv))for US only*

(88) Date of publication of the international search report:

26 January 2006

Published:

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*